MWM
ADPT icon

Melfa Wealth Management’s Adaptive Biotechnologies ADPT Stock Holding History

Melfa Wealth Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,100
Closed -$32.4K – 200
2024
Q1 		$32.4K Buy
+10,100
New +$39.1K 0.02% 195

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Melfa Wealth Management's ADPT Position: Q2 2024 in Review

Melfa Wealth Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2024, closing a stake of 10,100 shares — an estimated $32.4K sold.

Melfa Wealth Management first reported a position in ADPT in Q1 2024 and held it in 1 quarter. The position peaked at $32.4K in Q1 2024. 176 funds tracked by Wall St. Rank hold ADPT as of Q2 2024.

  • Melfa Wealth Management reported no remaining Adaptive Biotechnologies position as of Q2 2024 after selling out during the quarter.
  • Melfa Wealth Management sold 10,100 Adaptive Biotechnologies shares in Q2 2024, an estimated $32.4K.
  • Melfa Wealth Management first reported a position in Adaptive Biotechnologies in Q1 2024 and held it in 1 quarter.
  • Melfa Wealth Management's Adaptive Biotechnologies position peaked at $32.4K in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2024.

Based on Melfa Wealth Management's 13F filing for Q2 2024, filed 15 Jul 2024.